Results 151 to 160 of about 5,853,531 (371)
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, 2006 C Ronald, MacKenzie, Bruce N, Cronstein
openaire +4 more sources
Child Protection and Adult Mental Health. Conflict of Interest? Edited by A. Weir & A. Douglas. Oxford: Butterworth-Heinemann 1999. 211 pp. £16.99 (pb). ISBN 0-7506-2904-5 [PDF]
, 2000 Jean Harris‐Hendriks
openalex +1 more source
Molecular Oncology, EarlyView.Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop +10 more
wiley +1 more source
Conflict of interest disclosure: striking a balance?
European Journal of Health Economics, 2019 L. Garattini, A. Padula
semanticscholar +1 more source
Room G, 10/16/2000 9: 00 AM - 11: 00 AM (PS) Patient's Understanding of Investigator Conflict of Interest [PDF]
, 2000 Robert S. Greenberg, Curt I. Civin
openalex +1 more source
Conditional Allocation of Control Rights in Venture Capital Finance [PDF]
When a young entrepreneurial firm matures, it is often necessary to replace the founding entrepreneur by a professional manager. This replacement decision can be affected by the private benefits of control enjoyed by the entrepreneur which gives rise to ...
Gebhardt, Georg, Schmidt, Klaus M.
core
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source
Molecular Oncology, EarlyView.Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho +11 more
wiley +1 more source